Landmark Research on Oral Delivery System that Could Transform Diabetes Care Published in Nature Bio
Toralgen and Yale scientists demonstrate an oral drug delivery platform that will enable improved compliance and patient experience for biotherapeutics such as those used to treat diabetes.
READ MORE
Toralgen adds Ed Bastyr as Chief Medical Officer
INDIANAPOLIS, Indiana (April 28, 2021) – Toralgen, an Indiana-based biotechnology company focused on improving the delivery of biologics today announced the addition of Ed Bastyr III, MD to the newly created role of chief medical officer/clinical adviser.
READ MORE
GlobalData Healthcare coverage of Toralgen
GlobalData Healthcare highlights Toralgen's drug deliver platform potential in diabetes: "Toralgen’s technology provides a significant promise to oral delivery of major diabetic therapies"
READ MORE
StartUs Insights names Toralgen to Top 5 Drug Delivery Startup list
StartUs evaluated 266 emerging Biotech start-ups and highlighted Toralgen as one of 5 promising drug delivery startups.
READ MORE
Toralgen Closes $8.3 Million Seed Funding Roun
INDIANAPOLIS, IN., December 14, 2020 – Toralgen, an Indiana-based biotechnology company has announced the successful completion of its second seed funding round, raising a total of $8.3 million.
READ MORE
FiercePharma article: FDA let’s Toralgen’s insulin delivery nanopill into tech scheme
FIND OUT MORE
READ MORE
VIEW MORE